[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,776,408
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.16
  • Price/Sales 3.23
  • Price/Cash Flow 9.55
  • Price/Book 1.71

Options Overview Details

View History
  • Implied Volatility 41.32% (-0.93%)
  • Historical Volatility 35.12%
  • IV Percentile 86%
  • IV Rank 59.10%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 3) 8.58 (4.17%)
  • Put/Call Vol Ratio 0.70
  • Today's Volume 1,028
  • Volume Avg (30-Day) 1,477
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 53,916
  • Open Int (30-Day) 52,991
  • Expected Range 197.12 to 214.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.35
  • Number of Estimates 21
  • High Estimate $4.40
  • Low Estimate $2.33
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -38.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
192.18 +7.04%
on 06/08/26
219.72 -6.38%
on 06/29/26
+10.36 (+5.30%)
since 06/05/26
3-Month
171.22 +20.14%
on 04/13/26
219.72 -6.38%
on 06/29/26
+30.09 (+17.13%)
since 04/07/26
52-Week
121.05 +69.93%
on 07/21/25
219.72 -6.38%
on 06/29/26
+75.57 (+58.07%)
since 07/07/25

Most Recent Stories

More News
1 S&P 500 Stock with Promising Prospects and 2 We Question

1 S&P 500 Stock with Promising Prospects and 2 We Question

FOXA : 54.92 (-1.70%)
GEV : 1,077.08 (-6.51%)
BIIB : 205.70 (-1.32%)
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...

STOK : 33.02 (+1.82%)
BIIB : 205.70 (-1.32%)
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline...

BIIB : 205.70 (-1.32%)
Why Biogen (BIIB) Stock Is Up Today

Why Biogen (BIIB) Stock Is Up Today

BIIB : 205.70 (-1.32%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 205.70 (-1.32%)
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

QNTM : 3.32 (-3.49%)
QNTM.CN : 4.7500 (-2.06%)
CLNN : 6.12 (+1.83%)
RHHBY : 52.1700 (+1.12%)
SNY : 42.98 (+0.87%)
BIIB : 205.70 (-1.32%)
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)

Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)

BIIB : 205.70 (-1.32%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 205.70 (-1.32%)
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule...

BIIB : 205.70 (-1.32%)
3 Overrated Stocks Walking a Fine Line

3 Overrated Stocks Walking a Fine Line

RBCAA : 90.25 (-0.92%)
BIIB : 205.70 (-1.32%)
TCBK : 53.72 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 216.27
2nd Resistance Point 214.13
1st Resistance Point 209.92
Last Price 205.70
1st Support Level 203.57
2nd Support Level 201.43
3rd Support Level 197.22

See More

52-Week High 219.72
Last Price 205.70
Fibonacci 61.8% 182.03
Fibonacci 50% 170.39
Fibonacci 38.2% 158.74
52-Week Low 121.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.